Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. - Researchers evaluated the long-term efficacy and safety of infliximab (IFX), and IFX optimization when ocular remission was achieved in a large series of White patients with refractory uveitis due to Behçet disease (BD) being treated with infliximab (IFX). A multicenter study was conducted including IFX-treated patients with BD uveitis refractory to conventional immunosuppressant agents treated 103 patients/185 affected eyes with IFX as first biologic therapy in the following intervals: 3–5 mg/kg intravenous at 0, 2, 6, and then every 4–8 weeks. The findings revealed that in White patients with refractory BD uveitis, IFX appears to be effective and relatively safe. IFX optimization was found to be effective, safe, and cost-effective.